Barbarannamated Posted June 20, 2012 Share Posted June 20, 2012 (edited) This research elucidates the interdependence of all neurotransmitters in controlling body function. Melatonin and the pineal gland have long been associated with the sleep/wake cycle. This research incorporates the role of the adrenergic system in body diurnal patterns. __________________________________________________________________________________________________________ NOVEL MELATONIN-BLOCKING COMPLEX HELPS CONTROL BODY RHYTHMS http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001348 Recently published, data not yet available Citation: Weaver J (2012) PLoS Biol 10(6): e1001348. doi:10.1371/journal.pbio.1001348 CIRCADIAN-RELATED HETEROMERIZATION of ADRENERGIC and DOPAMINE D4 RECEPTORS MODULATES MELATONIN SYNTHESIS and RELEASE IN THE PINEAL GLAND Janelle Weaver* Freelance Science Writer, Glenwood Springs, Colorado, United States of America Published: June 19, 2012 Circadian rhythms are daily cycles that control our sleep-wake patterns, hormone release, and body temperature, and are found in virtually all life forms. Because our internal clock runs just over 24 hours, our bodies set it to match day length using environmental cues such as light. Information about light levels travels from the eyes to a brain structure called the pineal gland, which adjusts the internal clock by secreting melatonin at night. The synthesis and release of this sleep-inducing hormone is known to be regulated by a class of cell-surface proteins called adrenergic receptors. However, it has been unclear exactly what limits the daytime rates of melatonin production. This week in PLoS Biology, a team led by Peter McCormick of the University of Barcelona reports that adrenergic receptors form complexes with D4 dopamine receptors to block melatonin production during the day. The levels of these complexes (called heteromers) rise and fall in a circadian pattern—a phenomenon that has never before been reported for receptor heteromers. These findings elucidate the previously unknown role of D4 receptors in the pineal gland, and provide evidence for a novel molecular mechanism for controlling melatonin production in mammals. In the study, McCormick and his collaborators detected the D4-adrenergic receptor complexes in cells isolated from the rat pineal gland. After attaching DNA strands to distinct antibodies that bind to D4 receptors and adrenergic receptors, they found that the two different receptors were close enough for the DNA strands on their respecti antibodies to interact. This interaction occurred in pineal glands extracted just after sunrise but not at sunset, suggesting that the complexes form at the start of the light period, but their numbers diminish by the end of the day. To examine the functional role of the D4-adrenergic receptor complexes, McCormick and his team treated pineal glands with compounds that activate both types of receptors. Stimulation of D4 receptors interfered with the ability of adrenergic receptors to activate their target signaling pathways (ERK 1/2 and Akt/PKB) and thereby increase melatonin synthesis and release. This inhibitory effect occurred in pineal glands extracted at sunrise, when the complexes were present in the tissue, but not in pineal glands removed at sunset, when only adrenergic receptors were expressed. The newly identified complexes fit the classic definition of a heteromer because they take on biochemical and functional properties that are different from those of their individual units. Because these heteromers keep melatonin at low levels until nighttime, they could explain how the pineal gland is able to maintain precise control over the body's circadian rhythms. González S, Moreno-Delgado D, Moreno E, Pérez-Capote K, Franco R, et al. (2012) Circadian-Related Heteromerization of Adrenergic and Dopamine D 4 Receptors Modulates Melatonin Synthesis and Release in the Pineal Gland. doi:10.1371/journal.pbio.1001347 Edited June 21, 2012 by Altostrata added author name to conform to Creative Commons Attribution License Pristiq tapered over 8 months ending Spring 2011 after 18 years of polydrugging that began w/Zoloft for fatigue/general malaise (not mood). CURRENT: 1mg Klonopin qhs (SSRI bruxism), 75mg trazodone qhs, various hormonesLitigation for 11 years for Work-related injury, settled 2004. Involuntary medical retirement in 2001 (age 39). 2012 - brain MRI showing diffuse, chronic cerebrovascular damage/demyelination possibly vasculitis/cerebritis. Dx w/autoimmune polyendocrine failure.<p>2013 - Dx w/CNS Sjogren's Lupus (FANA antibodies first appeared in 1997 but missed by doc). Link to comment Share on other sites More sharing options...
Administrator Altostrata Posted June 21, 2012 Administrator Share Posted June 21, 2012 As this is an article by Weaver about a study conducted by McCormick et al (oddly, McCormick is not listed in the authors for the study), and not a study itself, I've moved it to Media. Also, edited reposting to conform to Creative Commons Attribution License: This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. This is not medical advice. Discuss any decisions about your medical care with a knowledgeable medical practitioner. "It has become appallingly obvious that our technology has surpassed our humanity." -- Albert Einstein All postings © copyrighted. Link to comment Share on other sites More sharing options...
Barbarannamated Posted June 21, 2012 Author Share Posted June 21, 2012 Thanks. I thought I may have posted in wrong area after it was done. Pristiq tapered over 8 months ending Spring 2011 after 18 years of polydrugging that began w/Zoloft for fatigue/general malaise (not mood). CURRENT: 1mg Klonopin qhs (SSRI bruxism), 75mg trazodone qhs, various hormonesLitigation for 11 years for Work-related injury, settled 2004. Involuntary medical retirement in 2001 (age 39). 2012 - brain MRI showing diffuse, chronic cerebrovascular damage/demyelination possibly vasculitis/cerebritis. Dx w/autoimmune polyendocrine failure.<p>2013 - Dx w/CNS Sjogren's Lupus (FANA antibodies first appeared in 1997 but missed by doc). Link to comment Share on other sites More sharing options...
Recommended Posts